Gymnema (Gymnema sylvestre) as a tool for helping with Blood sugar / diabetes support

Systematic review and meta-analysis of six randomized controlled trials in adults: Gymnema sylvestre supplementation significantly decreased triglycerides, total cholesterol, LDL cholesterol, fasting blood sugar and diastolic blood pressure, indicating benefit for both the lipid profile and glycaemic control.

Systematic review and meta-analysis of 10 trials (419 participants): Gymnema sylvestre supplementation significantly reduced fasting blood glucose, postprandial blood glucose and glycated haemoglobin (HbA1c) and lowered triglycerides and total cholesterol, supporting its use for glycaemic control in type 2 diabetes.

Review of plant-derived enzyme inhibitors with antidiabetic activity describing how species including Gymnema sylvestre lower blood glucose through mechanisms such as inhibition of intestinal alpha-glucosidase and alpha-amylase, stimulation of insulin secretion and reduced glucose absorption.

Randomized study in 50 patients with obesity comparing Gymnema sylvestre with berberine over three months: Gymnema sylvestre significantly reduced fasting glucose and resistin gene expression with minimal side effects, supporting an antidiabetic, insulin-sensitising effect.

Randomized controlled trial in 58 healthy adults: a 14-day intervention with Gymnema sylvestre (75 percent gymnemic acids), whose gymnemic acids block lingual sweet-taste receptors, reduced the pleasantness and intake of chocolate, illustrating the sweet-taste-suppressing mechanism underlying gymnema's use for blood-sugar and sugar-craving control.

Controlled open-label study supplementing 500 mg/day Gymnema sylvestre for 3 months in type 2 diabetics, reporting reductions in fasting and post-prandial blood glucose and glycated haemoglobin, reduced polyphagia and fatigue, and a favourable shift in lipid profile.

Clinical trial in 22 type 2 diabetic patients in which Gymnema sylvestre leaf extract (GS4, 400 mg/day) added to conventional oral hypoglycaemic drugs significantly lowered blood glucose, glycated haemoglobin and glycated plasma proteins and allowed conventional drug doses to be reduced, with five patients maintaining glucose control on GS4 alone.